2-Year Outcomes After Stenting of Lipid-Rich and Nonrich Coronary Plaques.
| Autor: | Yamamoto MH; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Maehara A; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York. Electronic address: amaehara@crf.org., Stone GW; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Kini AS; Division of Cardiology, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York., Brilakis ES; Veterans Affairs North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota., Rizik DG; HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona., Shunk K; San Francisco Veterans Affairs Medical Center, San Francisco, California; University of California, San Francisco, California., Powers ER; Medical University of South Carolina, Charleston, South Carolina., Tobis JM; University of California Los Angeles Medical Center, Los Angeles, California., Maini BS; Tenet Healthcare Corporation, Delray Beach, Florida; Florida Atlantic University, Boca Raton, Florida., Dixon SR; Beaumont Hospital, Royal Oak, Michigan., Goldstein JA; Beaumont Hospital, Royal Oak, Michigan., Petersen JL 2nd; Swedish Medical Center, Seattle, Washington., Généreux P; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey; Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada., Shah PR; InfraReDx, Burlington, Massachusetts., Crowley A; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Nicholls SJ; Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia., Mintz GS; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York., Muller JE; Brigham and Women's Hospital, Boston, Massachusetts., Weisz G; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; Montefiore Medical Center, Bronx, New York. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of the American College of Cardiology [J Am Coll Cardiol] 2020 Mar 31; Vol. 75 (12), pp. 1371-1382. |
| DOI: | 10.1016/j.jacc.2020.01.044 |
| Abstrakt: | Background: Autopsy studies suggest that implanting stents in lipid-rich plaque (LRP) may be associated with adverse outcomes. Objectives: The purpose of this study was to evaluate the association between LRP detected by near-infrared spectroscopy (NIRS) and clinical outcomes in patients with coronary artery disease treated with contemporary drug-eluting stents. Methods: In this prospective, multicenter registry, NIRS was performed in patients undergoing coronary angiography and possible percutaneous coronary intervention (PCI). Lipid core burden index (LCBI) was calculated as the fraction of pixels with the probability of LRP >0.6 within a region of interest. MaxLCBI Results: Among 1,999 patients who were enrolled in the COLOR (Chemometric Observations of Lipid Core Plaques of Interest in Native Coronary Arteries Registry), PCI was performed in 1,621 patients and MACE occurred in 18.0% of patients, of which 8.3% were culprit lesion-related, 10.7% were nonculprit lesion-related, and 3.1% were indeterminate during 2-year follow-up. Complications from NIRS imaging occurred in 9 patients (0.45%), which resulted in 1 peri-procedural myocardial infarction and 1 emergent coronary bypass. Pre-PCI NIRS imaging was obtained in 1,189 patients, and the 2-year rate of culprit lesion-related MACE was not significantly associated with maxLCBI Conclusions: Following PCI with contemporary drug-eluting stents, stent implantation in NIRS-defined LRPs was not associated with increased periprocedural or late adverse outcomes compared with those without significant lipid. (Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|